Sebastian Berg

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5157681/publications.pdf

Version: 2024-02-01

448 papers

11,471 citations

53 h-index ⁵⁸⁵⁴⁹ **82**

g-index

454 all docs

454 docs citations

times ranked

454

12411 citing authors

#	Article	IF	CITATIONS
1	Perioperative Outcomes of Robot-Assisted Radical Prostatectomy Compared With Open Radical Prostatectomy: Results From the Nationwide Inpatient Sample. European Urology, 2012, 61, 679-685.	0.9	345
2	Propensity-Matched Comparison of Morbidity and Costs of Open and Robot-Assisted Radical Cystectomies: A Contemporary Population-Based Analysis in the United States. European Urology, 2014, 66, 569-576.	0.9	205
3	Lack of reduction in racial disparities in cancerâ€specific mortality over a 20â€year period. Cancer, 2014, 120, 1532-1539.	2.0	204
4	Practice Patterns and Outcomes of Open and Minimally Invasive Partial Nephrectomy Since the Introduction of Robotic Partial Nephrectomy: Results from the Nationwide Inpatient Sample. Journal of Urology, 2014, 191, 907-913.	0.2	197
5	Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study. Journal of Clinical Oncology, 2016, 34, 3267-3275.	0.8	185
6	Robot-assisted Versus Open Radical Prostatectomy: A Contemporary Analysis of an All-payer Discharge Database. European Urology, 2016, 70, 837-845.	0.9	178
7	Cancer Screening Tests and Cancer Diagnoses During the COVID-19 Pandemic. JAMA Oncology, 2021, 7, 458.	3.4	177
8	A Systematic Review of the Volume–Outcome Relationship for Radical Prostatectomy. European Urology, 2013, 64, 786-798.	0.9	172
9	Venous Thromboembolism After Major Cancer Surgery. JAMA Surgery, 2014, 149, 43.	2.2	158
10	Prediction of 90-day Mortality After Radical Cystectomy for Bladder Cancer in a Prospective European Multicenter Cohort. European Urology, 2014, 66, 156-163.	0.9	156
11	Neoadjuvant chemotherapy prior to radical cystectomy for muscleâ€invasive bladder cancer with variant histology. Cancer, 2017, 123, 4346-4355.	2.0	138
12	Identifying Optimal Candidates for Local Treatment of the Primary Tumor Among Patients Diagnosed with Metastatic Prostate Cancer: A SEER-based Study. European Urology, 2015, 67, 3-6.	0.9	136
13	The Impact of Local Treatment on Overall Survival in Patients with Metastatic Prostate Cancer on Diagnosis: A National Cancer Data Base Analysis. European Urology, 2017, 72, 14-19.	0.9	128
14	Association of Androgen Deprivation Therapy With Depression in Localized Prostate Cancer. Journal of Clinical Oncology, 2016, 34, 1905-1912.	0.8	121
15	Cancer-Specific Outcomes Among Young Adults Without Health Insurance. Journal of Clinical Oncology, 2014, 32, 2025-2030.	0.8	112
16	Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Critical Reviews in Oncology/Hematology, 2015, 94, 228-237.	2.0	111
17	Extended Versus Limited Pelvic Lymph Node Dissection During Radical Prostatectomy for Intermediate- and High-risk Prostate Cancer: Early Oncological Outcomes from a Randomized Phase 3 Trial. European Urology, 2021, 79, 595-604.	0.9	111
18	Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder. European Urology, 2017, 72, 483-487.	0.9	110

#	Article	IF	Citations
19	Effect of Minimally Invasive Surgery on the Risk for Surgical Site Infections. JAMA Surgery, 2014, 149, 1039.	2.2	109
20	Prostate-Specific Antigen Screening After 2012 US Preventive Services Task Force Recommendations. JAMA - Journal of the American Medical Association, 2015, 314, 2077.	3.8	105
21	Effectiveness of Adjuvant Chemotherapy After Radical Nephroureterectomy for Locally Advanced and/or Positive Regional Lymph Node Upper Tract Urothelial Carcinoma. Journal of Clinical Oncology, 2017, 35, 852-860.	0.8	104
22	Racial/Ethnic Disparities in Perioperative Outcomes of Major Procedures. Annals of Surgery, 2015, 262, 955-964.	2.1	101
23	Comparative Effectiveness of Robot-assisted Versus Open Radical Prostatectomy Cancer Control. European Urology, 2014, 66, 666-672.	0.9	97
24	Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy. JAMA Oncology, 2016, 2, 500.	3.4	94
25	Impact of travel distance to the treatment facility on overall mortality in US patients with prostate cancer. Cancer, 2017, 123, 3241-3252.	2.0	89
26	Emergency Department Visits in the United States for Upper Urinary Tract Stones: Trends in Hospitalization and Charges. Journal of Urology, 2014, 191, 90-96.	0.2	88
27	Assessment of Time-to-Treatment Initiation and Survival in a Cohort of Patients With Common Cancers. JAMA Network Open, 2020, 3, e2030072.	2.8	87
28	Trends in Disparate Treatment of African American Men With Localized Prostate Cancer Across National Comprehensive Cancer Network Risk Groups. Urology, 2014, 84, 386-392.	0.5	86
29	Racial Differences in the Surgical Care of Medicare Beneficiaries With Localized Prostate Cancer. JAMA Oncology, 2016, 2, 85.	3.4	86
30	Getting back to equal: The influence of insurance status on racial disparities in the treatment of African American men with high-risk prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 1285-1291.	0.8	81
31	Contemporary incidence and mortality rates of kidney cancer in the United States. Canadian Urological Association Journal, 2014, 8, 247.	0.3	78
32	Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone. Journal of Clinical Oncology, 2019, 37, 923-931.	0.8	78
33	The impact of androgenâ€deprivation therapy (<scp>ADT</scp>) on the risk of cardiovascular (<scp>CV</scp>) events in patients with nonâ€metastatic prostate cancer: a populationâ€based study. BJU International, 2014, 114, E82-E89.	1.3	77
34	Impact of Centralizing Care for Genitourinary Malignancies to High-volume Providers: A Systematic Review. European Urology Oncology, 2019, 2, 265-273.	2.6	75
35	Cost Implications and Complications of Overtreatment of Low-Risk Prostate Cancer in the United States. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 61-68.	2.3	72
36	Clinical and Genomic Characterization of Low–Prostate-specific Antigen, High-grade Prostate Cancer. European Urology, 2018, 74, 146-154.	0.9	72

#	Article	IF	Citations
37	The Effect of Neoadjuvant Chemotherapy on Perioperative Outcomes in Patients Who Have Bladder Cancer Treated with Radical Cystectomy: A Population-based Study. European Urology, 2014, 66, 561-568.	0.9	70
38	Efficacy of High-Intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Score–Weighted Analysis From the National Cancer Data Base. Journal of Clinical Oncology, 2016, 34, 3529-3536.	0.8	70
39	Cognitive Impairment in Men with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis. Journal of Urology, 2018, 199, 1417-1425.	0.2	70
40	Impact of smoking on perioperative outcomes after major surgery. American Journal of Surgery, 2015, 210, 221-229.e6.	0.9	69
41	Systematic Review of the Volume–Outcome Relationship for Radical Prostatectomy. European Urology Focus, 2018, 4, 775-789.	1.6	68
42	Association of androgenâ€deprivation therapy with excess cardiacâ€specific mortality in men with prostate cancer. BJU International, 2015, 116, 358-365.	1.3	66
43	Disparities in access to care at highâ€volume institutions for uroâ€oncologic procedures. Cancer, 2012, 118, 4421-4426.	2.0	65
44	Cancer-Specific Mortality of Asian Americans Diagnosed With Cancer: A Nationwide Population-Based Assessment. Journal of the National Cancer Institute, 2015, 107, djv054-djv054.	3.0	63
45	The influence of marital status on the use of breast, cervical, and colorectal cancer screening. Preventive Medicine, 2016, 89, 140-145.	1.6	63
46	Effectiveness of adjuvant chemotherapy after radical nephroureterectomy for locally advanced and/or positive regional lymph node upper tract urothelial carcinoma Journal of Clinical Oncology, 2017, 35, 305-305.	0.8	63
47	Diagnosis and Staging of Bladder Cancer. Hematology/Oncology Clinics of North America, 2015, 29, 205-218.	0.9	62
48	Variations in the Costs of Radical Cystectomy for Bladder Cancer in the USA. European Urology, 2018, 73, 374-382.	0.9	62
49	Association of Care at Minority-Serving vs Non–Minority-Serving Hospitals With Use of Palliative Care Among Racial/Ethnic Minorities With Metastatic Cancer in the United States. JAMA Network Open, 2019, 2, e187633.	2.8	60
50	Mental health outcomes in elderly men with prostate cancer1Equal contribution Urologic Oncology: Seminars and Original Investigations, 2014, 32, 1333-1340.	0.8	59
51	Effectiveness of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Current Real World Setting in the USA. European Urology Oncology, 2018, 1, 83-90.	2.6	59
52	Adjuvant Chemotherapy vs Observation for Patients With Adverse Pathologic Features at Radical Cystectomy Previously Treated With Neoadjuvant Chemotherapy. JAMA Oncology, 2018, 4, 225.	3.4	58
53	Disparities in Access to Hospitals with Robotic Surgery for Patients with Prostate Cancer Undergoing Radical Prostatectomy. Journal of Urology, 2013, 189, 514-520.	0.2	57
54	Predicting Life Expectancy in Men Diagnosed with Prostate Cancer. European Urology, 2015, 68, 756-765.	0.9	57

#	Article	IF	CITATIONS
55	Investigation of Suicidality and Psychological Adverse Events in Patients Treated With Finasteride. JAMA Dermatology, 2021, 157, 35.	2.0	57
56	Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscleâ€invasive carcinoma of the bladder: Does histologic subtype matter?. Cancer, 2019, 125, 1449-1458.	2.0	56
57	Income inequality and treatment of African American men with high-risk prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 18.e7-18.e13.	0.8	53
58	Evaluation of the contribution of demographics, access to health care, treatment, and tumor characteristics to racial differences in survival of advanced prostate cancer. Prostate Cancer and Prostatic Diseases, 2019, 22, 125-136.	2.0	53
59	Comparative effectiveness of robot-assisted vs. open radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 88.e1-88.e9.	0.8	52
60	Short-term perioperative outcomes of patients treated with radical cystectomy for bladder cancer included in the National Surgical Quality Improvement Program (NSQIP) database. Canadian Urological Association Journal, 2014, 8, 681.	0.3	51
61	Where Is the Value in Ambulatory Versus Inpatient Surgery?. Annals of Surgery, 2021, 273, 909-916.	2.1	51
62	Predictors of 30-day acute kidney injury following radical and partial nephrectomy for renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 1259-1266.	0.8	50
63	Photoselective Vaporization of the Prostate for Benign Prostatic Hyperplasia Using the 180 Watt System: Multicenter Study of the Impact of Prostate Size on Safety and Outcomes. Journal of Urology, 2015, 194, 462-469.	0.2	50
64	Association of Cigarette Smoking and Smoking Cessation with Biochemical Recurrence of Prostate Cancer in Patients Treated with Radical Prostatectomy. European Urology, 2015, 68, 949-956.	0.9	50
65	Recurrence in Localized Renal Cell Carcinoma: a Systematic Review of Contemporary Data. Current Urology Reports, 2017, 18, 15.	1.0	49
66	Secondary data sources for health services research in urologic oncology. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 165-173.	0.8	48
67	Effect of Medicaid Expansion on Colorectal Cancer Screening Rates. Diseases of the Colon and Rectum, 2019, 62, 97-103.	0.7	48
68	Predictors of early continence following robot-assisted radical prostatectomy. Canadian Urological Association Journal, 2015, 9, 93.	0.3	47
69	The impact of resident involvement in minimally-invasive urologic oncology procedures. Canadian Urological Association Journal, 2014, 8, 334.	0.3	46
70	Racial Disparities in Prostate Cancer–Specific Mortality in Men With Low-Risk Prostate Cancer. Clinical Genitourinary Cancer, 2014, 12, e189-e195.	0.9	46
71	Tobacco-Specific Carcinogens Induce Hypermethylation, DNA Adducts, and DNA Damage in Bladder Cancer. Cancer Prevention Research, 2017, 10, 588-597.	0.7	46
72	Efficacy of Local Treatment in Prostate Cancer Patients with Clinically Pelvic Lymph Node-positive Disease at Initial Diagnosis. European Urology, 2018, 73, 452-461.	0.9	46

#	Article	IF	Citations
73	Gleason score 5 + 3 = 8 prostate cancer: much more like Gleason score 9?. BJU International, 2016, 118, 95-101.	1.3	45
74	Racial and Ethnic Variation in PSA Testing and Prostate Cancer Incidence Following the 2012 USPSTF Recommendation. Journal of the National Cancer Institute, 2021, 113, 719-726.	3.0	45
75	Incidence, admission rates, and economic burden of pediatric emergency department visits for urinary tract infection: Data from the nationwide emergency department sample, 2006 to 2011. Journal of Pediatric Urology, 2015, 11, 246.e1-246.e8.	0.6	44
76	Secondary data analysis. Current Opinion in Urology, 2017, 27, 354-359.	0.9	44
77	Complications After Metastasectomy for Renal Cell Carcinoma—A Population-based Assessment. European Urology, 2017, 72, 171-174.	0.9	44
78	The Development of Brain Metastases in Patients with Renal Cell Carcinoma: Epidemiologic Trends, Survival, and Clinical Risk Factors Using a Population-based Cohort. European Urology Focus, 2019, 5, 474-481.	1.6	44
79	Patterns of Declining Use and the Adverse Effect of Primary Androgen Deprivation on All-cause Mortality in Elderly Men with Prostate Cancer. European Urology, 2015, 68, 32-39.	0.9	43
80	Trends of acute kidney injury after radical or partial nephrectomy for renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 293.e1-293.e10.	0.8	43
81	Racial Disparity in Delivering Definitive Therapy for Intermediate/High-risk Localized Prostate Cancer: The Impact of Facility Features and Socioeconomic Characteristics. European Urology, 2018, 73, 445-451.	0.9	43
82	Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men. European Urology, 2019, 75, 399-407.	0.9	43
83	Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in Patients with High-risk Localized Prostate Cancer. European Urology, 2019, 75, 552-555.	0.9	43
84	Contemporary Trends in the Incidence of Metastatic Prostate Cancer Among US Men: Results from Nationwide Analyses. European Urology Focus, 2019, 5, 77-80.	1.6	43
85	Robot-assisted versus laparoscopic nephroureterectomy for uppertract urothelial cancer: A population-based assessment of costs and perioperative outcomes. Canadian Urological Association Journal, 2014, 8, 695.	0.3	42
86	Age-stratified distribution of metastatic sites in bladder cancer: A population-based analysis. Canadian Urological Association Journal, 2014, 8, 148.	0.3	42
87	Surgeon and Hospital Level Variation in the Costs of Robot-Assisted Radical Prostatectomy. Journal of Urology, 2016, 196, 1090-1095.	0.2	42
88	The association of hypoalbuminemia with early perioperative outcomes $\hat{a} \in A$ comprehensive assessment across 16 major procedures. American Journal of Surgery, 2017, 214, 871-883.	0.9	42
89	Morbidity and mortality of radical prostatectomy differs by insurance status. Cancer, 2012, 118, 1803-1810.	2.0	41
90	Development and Validation of a Bedside Risk Assessment for Sustained Prescription Opioid Use After Surgery. JAMA Network Open, 2019, 2, e196673.	2.8	41

#	Article	IF	CITATIONS
91	Variation in Pelvic Lymph Node Dissection among Patients Undergoing Radical Prostatectomy by Hospital Characteristics and Surgical Approach: Results from the National Cancer Database. Journal of Urology, 2015, 193, 820-825.	0.2	40
92	Definition and Validation of "Favorable High-Risk Prostate Cancer†Implications for Personalizing Treatment of Radiation-Managed Patients. International Journal of Radiation Oncology Biology Physics, 2015, 93, 828-835.	0.4	40
93	Efficacy of Systemic Chemotherapy Plus Radical Nephroureterectomy for Metastatic Upper Tract Urothelial Carcinoma. European Urology, 2017, 71, 714-718.	0.9	40
94	Variation in the use of active surveillance for lowâ€risk prostate cancer. Cancer, 2018, 124, 55-64.	2.0	40
95	Evaluating the cost of surveillance for non-muscle-invasive bladder cancer: an analysis based on risk categories. World Journal of Urology, 2019, 37, 2059-2065.	1.2	40
96	Risk of Upgrading and Upstaging Among 10 000 Patients with Gleason 3 + 4 Favorable Intermediate-risk Prostate Cancer. European Urology Focus, 2019, 5, 69-76.	1.6	40
97	Suicide and accidental deaths among patients with nonâ€metastatic prostate cancer. BJU International, 2016, 118, 286-297.	1.3	39
98	Contemporary national trends in prostate cancer risk profile at diagnosis. Prostate Cancer and Prostatic Diseases, 2020, 23, 81-87.	2.0	39
99	Racial Disparities in End-of-Life Care Among Patients With Prostate Cancer: A Population-Based Study. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1131-1138.	2.3	37
100	Hepatotoxicity with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A meta-analysis of randomized clinical trials. Critical Reviews in Oncology/Hematology, 2015, 93, 257-276.	2.0	37
101	Racial disparity in quality of care and overall survival among black vs. white patients with muscle-invasive bladder cancer treated with radical cystectomy: A national cancer database analysis. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 469.e1-469.e11.	0.8	37
102	Geographic Distribution of Racial Differences in Prostate Cancer Mortality. JAMA Network Open, 2020, 3, e201839.	2.8	37
103	The Effect of Resident Involvement on Perioperative Outcomes in Transurethral Urologic Surgeries. Journal of Surgical Education, 2015, 72, 1018-1025.	1.2	36
104	Causes of hospital readmissions after urologic cancer surgery. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 236.e1-236.e11.	0.8	36
105	Minimally invasive vs open nephrectomy in the modern era: does approach matter?. World Journal of Urology, 2017, 35, 1557-1568.	1.2	36
106	Cardiovascular Mortality in Patients With Metastatic Prostate Cancer Exposed to Androgen Deprivation Therapy: A Population-Based Study. Clinical Genitourinary Cancer, 2015, 13, e123-e130.	0.9	35
107	The impact of hospital volume, residency, and fellowship training on perioperative outcomes after radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 29.e13-29.e20.	0.8	34
108	Asian Americans and prostate cancer: A nationwide population-based analysis. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 233.e7-233.e15.	0.8	34

#	Article	IF	CITATIONS
109	Association between androgen deprivation therapy and anxiety among 78 000 patients with localized prostate cancer. International Journal of Urology, 2017, 24, 743-748.	0.5	34
110	Decision Support with the Personal Patient Profile-Prostate: A Multicenter Randomized Trial. Journal of Urology, 2018, 199, 89-97.	0.2	34
111	Quality Indicators for Bladder Cancer Services: A Collaborative Review. European Urology, 2020, 78, 43-59.	0.9	34
112	Radical Prostatectomy at Academic Versus Nonacademic Institutions: A Population Based Analysis. Journal of Urology, 2011, 186, 1849-1854.	0.2	33
113	Contemporary Nationwide Patterns of Self-reported Prostate-Specific Antigen Screening. JAMA Internal Medicine, 2014, 174, 1839.	2.6	33
114	Determinants of cancer screening in Asian-Americans. Cancer Causes and Control, 2016, 27, 989-998.	0.8	33
115	The Association between Mortality and Distance to Treatment Facility in Patients with Muscle Invasive Bladder Cancer. Journal of Urology, 2018, 199, 424-429.	0.2	33
116	Analysis of Surgical Volume in Military Medical Treatment Facilities and Clinical Combat Readiness of US Military Surgeons. JAMA Surgery, 2022, 157, 43.	2.2	33
117	Determinants of Prostate Specific Antigen Screening among Black Men in the United States in the Contemporary Era. Journal of Urology, 2016, 195, 913-918.	0.2	32
118	Differences in Prostate-Specific Antigen Testing Among Urologists and Primary Care Physicians Following the 2012 USPSTF Recommendations. JAMA Internal Medicine, 2016, 176, 546.	2.6	32
119	Predictors, utilization patterns, and overall survival of patients undergoing metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy. European Journal of Surgical Oncology, 2018, 44, 1439-1445.	0.5	32
120	Cytoreductive Nephrectomy: Assessing the Generalizability of the CARMENA Trial to Real-world National Cancer Data Base Cases. European Urology, 2019, 75, 352-353.	0.9	32
121	A Surveillance, Epidemiology and End Results (<scp>SEER</scp>) database malfunction: perceptions, pitfalls and verities. BJU International, 2016, 117, 551-552.	1.3	31
122	Morbidity and Mortality of Locally Advanced Prostate Cancer: A Population Based Analysis Comparing Radical Prostatectomy versus External Beam Radiation. Journal of Urology, 2017, 198, 1061-1068.	0.2	31
123	Liver Disease in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer. Journal of Urology, 2018, 200, 573-581.	0.2	31
124	Sex-specific Differences in the Quality of Treatment of Muscle-invasive Bladder Cancer Do Not Explain the Overall Survival Discrepancy. European Urology Focus, 2021, 7, 124-131.	1.6	31
125	Quality of Care in the Treatment of Localized Intermediate and High Risk Prostate Cancer at Minority Serving Hospitals. Journal of Urology, 2019, 201, 735-741.	0.2	31
126	Is there any evidence of a "July effect―in patients undergoing major cancer surgery?. Canadian Journal of Surgery, 2014, 57, 82-88.	0.5	30

#	Article	IF	Citations
127	Associations of specific postoperative complications with costs after radical cystectomy. BJU International, 2018, 121, 428-436.	1.3	30
128	How Do Presenting Symptoms and Outcomes Differ by Race/Ethnicity Among Hospitalized Patients With Coronavirus Disease 2019 Infection? Experience in Massachusetts. Clinical Infectious Diseases, 2021, 73, e4131-e4138.	2.9	30
129	Gonadotropin-releasing Hormone Agonists and Acute Kidney Injury in Patients with Prostate Cancer. European Urology, 2014, 66, 1125-1132.	0.9	29
130	Difluoro-dioxolo-benzoimidazol-benzamides As Potent Inhibitors of CK1δ and Îμ with Nanomolar Inhibitory Activity on Cancer Cell Proliferation. Journal of Medicinal Chemistry, 2014, 57, 7933-7946.	2.9	29
131	The influence of physician recommendation on prostate-specific antigen screening. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 424.e1-424.e7.	0.8	28
132	Sepsis after major cancer surgery. Journal of Surgical Research, 2015, 193, 788-794.	0.8	28
133	Assessment of energy density usage during 180W lithium triborate laser photoselective vaporization of the prostate for benign prostatic hyperplasia. Is there an optimum amount of kiloâ€Joules per gram of prostate?. BJU International, 2016, 118, 633-640.	1.3	28
134	Prostate Cancer Screening in Early Medicaid Expansion States. Journal of Urology, 2018, 199, 81-88.	0.2	28
135	National sociodemographic disparities in the treatment of highâ€risk prostate cancer: Do academic cancer centers perform better than community cancer centers?. Cancer, 2016, 122, 3371-3377.	2.0	27
136	An Evaluation of the Timing of Surgical Complications Following Radical Cystectomy: Data From the American College of Surgeons National Surgical Quality Improvement Program. Urology, 2017, 103, 91-98.	0.5	27
137	Impact of testosterone replacement therapy on thromboembolism, heart disease and obstructive sleep apnoea in men. BJU International, 2018, 121, 811-818.	1.3	27
138	Value-Based Healthcare in Urology: A Collaborative Review. European Urology, 2021, 79, 571-585.	0.9	27
139	Laparoscopic Radical Nephrectomy vs Laparoscopic or Open Partial Nephrectomy for T1 Renal Cell Carcinoma: Comparison of Complication Rates in Elderly Patients During the Initial Phase of Adoption. Urology, 2014, 83, 1285-1293.	0.5	26
140	An evaluation of the timing of surgical complications following nephrectomy: data from the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP). World Journal of Urology, 2015, 33, 2031-2038.	1.2	26
141	Access denied: The relationship between patient insurance status and access to highâ€volume hospitals. Cancer, 2021, 127, 577-585.	2.0	26
142	Improvement of racial disparities with respect to the utilization of minimally invasive radical prostatectomy in the United States. Cancer, 2012, 118, 1894-1900.	2.0	25
143	A population-based competing-risks analysis of survival after nephrectomy for renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 46.e1-46.e7.	0.8	25
144	Minimally Invasive vs Open Pyeloplasty in Children: The Differential Effect of Procedure Volume on Operative Outcomes. Urology, 2014, 84, 180-184.	0.5	24

#	Article	IF	Citations
145	Is there a relationship between leapfrog volume thresholds and perioperative outcomes after radical cystectomy?. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 27.e7-27.e13.	0.8	24
146	The burden of skeletal-related events in patients with prostate cancer and bone metastasis. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 17.e9-17.e18.	0.8	24
147	Trends in Surgical Volume in the Military Health Systemâ€"A Potential Threat to Mission Readiness. Military Medicine, 2021, 186, 646-650.	0.4	24
148	Combined External Beam Radiation Therapy and Brachytherapy versus Radical Prostatectomy with Adjuvant Radiation Therapy for Gleason 9-10 Prostate Cancer. Journal of Urology, 2019, 202, 973-978.	0.2	24
149	Association Between Older Age and Increasing Gleason Score. Clinical Genitourinary Cancer, 2015, 13, 525-530.e3.	0.9	23
150	A Comparison of 30-Day Perioperative Outcomes in Open Versus Minimally Invasive Nephroureterectomy for Upper Tract Urothelial Carcinoma: Analysis of 896 Patients from the American College of Surgeons-National Surgical Quality Improvement Program Database. Journal of Endourology, 2015, 29, 1052-1058.	1.1	23
151	Wound dehiscence in a sample of $1\hat{A}776$ cystectomies: identification of predictors and implications for outcomes. BJU International, 2016, 117, E95-E101.	1.3	23
152	The Rise of Robotic Surgery in the New Millennium. Journal of Urology, 2017, 197, S213-S215.	0.2	23
153	Comparison of Hospital Readmission After Total Hip and Total Knee Arthroplasty vs Spinal Surgery After Implementation of the Hospital Readmissions Reduction Program. JAMA Network Open, 2019, 2, e194634.	2.8	23
154	Recovery of cancer screening tests and possible associated disparities after the first peak of the COVID-19 pandemic. Cancer Cell, 2021, 39, 1042-1044.	7.7	23
155	Discharge patterns after radical prostatectomy in the United States of America. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 1022-1032.	0.8	22
156	Optimal timing of early versus delayed adjuvant radiotherapy following radical prostatectomy for locally advanced prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 303-308.	0.8	22
157	Doseâ€dependent effect of androgen deprivation therapy for localized prostate cancer on adverse cardiac events. BJU International, 2016, 118, 221-229.	1.3	22
158	Risk of prostate cancer mortality in men with a history of prior cancer. BJU International, 2016, 117, E20-8.	1.3	22
159	Racial differences in prostate-specific antigen–based prostate cancer screening: State-by-state and region-by-region analyses. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 460.e9-460.e20.	0.8	22
160	Generalizability of the Prostate Cancer Intervention Versus Observation Trial (PIVOT) Results to Contemporary North American Men with Prostate Cancer. European Urology, 2017, 71, 511-514.	0.9	22
161	Racial Disparities in Treatment for Rectal Cancer at Minority-Serving Hospitals. Journal of Gastrointestinal Surgery, 2021, 25, 1847-1856.	0.9	22
162	Robotic nephrolithotomy and pyelolithotomy with utilization of the robotic ultrasound probe. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2014, 40, 125-126.	0.7	21

#	Article	IF	Citations
163	Racial disparities in an aging population: The relationship between age and race in the management of African American men with high-risk prostate cancer. Journal of Geriatric Oncology, 2014, 5, 352-358.	0.5	21
164	Who Bears the Greatest Burden of Aggressive Treatment of Indolent Prostate Cancer?. American Journal of Medicine, 2015, 128, 609-616.	0.6	21
165	Burden of Hospital Admissions and Utilization of Hospice Care in Metastatic Prostate Cancer Patients. Urology, 2015, 85, 343-350.	0.5	21
166	The Impact of Resident Involvement in Male One-stage Anterior Urethroplasties. Urology, 2015, 85, 937-941.	0.5	21
167	Novel biomarkers of acute kidney injury: Evaluation and evidence in urologic surgery. World Journal of Nephrology, 2015, 4, 160.	0.8	21
168	Temporal trends in receipt of adequate lymphadenectomy in bladder cancer 1988 to 2010. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 504.e9-504.e17.	0.8	21
169	The effect of treatment at minority-serving hospitals on outcomes for bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 238.e7-238.e17.	0.8	21
170	Survival benefit of definitive therapy in patients with clinically advanced prostate cancer: estimations of the number needed to treat based on competingâ€risks analysis. BJU International, 2014, 114, E62-E69.	1.3	20
171	Reassessing the value of highâ€volume cancer care in the era of precision medicine. Cancer, 2018, 124, 1319-1321.	2.0	20
172	Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. European Urology, 2018, 73, 262-270.	0.9	20
173	Trends in Breast, Colorectal, and Cervical Cancer Incidence Following the Affordable Care Act. JAMA Oncology, 2018, 4, 128.	3.4	20
174	Neoadjuvant Androgen Deprivation Therapy Prior to Radical Prostatectomy: Recent Trends in Utilization and Association with Postoperative Surgical Margin Status. Annals of Surgical Oncology, 2019, 26, 297-305.	0.7	20
175	Impact of tumor, treatment, and access on outcomes in bladder cancer: Can equal access overcome raceâ€based differences in survival?. Cancer, 2019, 125, 1319-1329.	2.0	20
176	Risk of Dementia and Depression in Young and Middle-aged Men Presenting with Nonmetastatic Prostate Cancer Treated with Androgen Deprivation Therapy. European Urology Oncology, 2021, 4, 66-72.	2.6	20
177	The Health Care Burden of Skeletal Related Events in Patients with Renal Cell Carcinoma and Bone Metastasis. Journal of Urology, 2014, 191, 1678-1684.	0.2	19
178	The impact of Medicare eligibility on cancer screening behaviors. Preventive Medicine, 2016, 85, 47-52.	1.6	19
179	Tumor volume improves the long-term prediction of biochemical recurrence-free survival after radical prostatectomy for localized prostate cancer with positive surgical margins. World Journal of Urology, 2017, 35, 199-206.	1.2	19
180	Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma. , 2019, 7, 289.		19

#	Article	IF	CITATIONS
181	The impact of underinsurance on bladder cancer diagnosis, survival, and care delivery for individuals under the age of 65Âyears. Cancer, 2020, 126, 496-505.	2.0	19
182	Early Impact of the Affordable Care Act and Medicaid Expansion on Racial and Socioeconomic Disparities in Cancer Care. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 163-167.	0.6	19
183	Impact of health literacy on shared decision making for prostateâ€specific antigen screening in the United States. Cancer, 2021, 127, 249-256.	2.0	19
184	Effect of Nodal Metastases on Cancer-specific Mortality After Cytoreductive Nephrectomy. Annals of Surgical Oncology, 2013, 20, 2096-2102.	0.7	18
185	Urolithiasis and Urinary Tract Infection Among Patients With Inflammatory Bowel Disease: A Review of US Emergency Department Visits between 2006 and 2009. Urology, 2015, 85, 764-770.	0.5	18
186	Racial Disparities in Partial Nephrectomy Persist Across Hospital Types: Results From a Population-based Cohort. Urology, 2016, 90, 69-75.	0.5	18
187	Accountable care organizations and the use of cancer screening. Preventive Medicine, 2017, 101, 15-17.	1.6	18
188	Effectiveness of Adjuvant Chemotherapy After Radical Cystectomy for Locally Advanced and/or Pelvic Lymph Node–Positive Muscle-invasive Urothelial Carcinoma of the Bladder: A Propensity Score–Weighted Competing Risks Analysis. European Urology Focus, 2018, 4, 252-259.	1.6	18
189	Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9–10 Prostate Cancer. European Urology, 2019, 75, 35-41.	0.9	18
190	Long-term Risk of Recurrence in Surgically Treated Renal Cell Carcinoma: A Post Hoc Analysis of the Eastern Cooperative Oncology Group—American College of Radiology Imaging Network E2805 Trial Cohort. European Urology, 2020, 77, 277-281.	0.9	18
191	Assessment of Out-of-Pocket Costs for Robotic Cancer Surgery in US Adults. JAMA Network Open, 2020, 3, e1919185.	2.8	18
192	Prostate Cancer Disparities in Risk Group at Presentation and Access to Treatment for Asian Americans, Native Hawaiians, and Pacific Islanders: A Study With Disaggregated Ethnic Groups. JCO Oncology Practice, 2022, 18, e204-e218.	1.4	18
193	Leapfrog volume thresholds and perioperative complications after radical prostatectomy. Cancer, 2012, 118, 4991-4998.	2.0	17
194	Pediatric Nephrectomy: Incidence, Indications and Use of Minimally Invasive Techniques. Journal of Urology, 2014, 191, 764-770.	0.2	17
195	Weight Gain on Androgen Deprivation Therapy: Which Patients Are at Highest Risk?. Urology, 2014, 83, 1316-1321.	0.5	17
196	The Impact of Insurance Status on Tumor Characteristics and Treatment Selection in Contemporary Patients With Prostate Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1351-1358.	2.3	17
197	Significant increase in prostatectomy and decrease in radiation for clinical T3 prostate cancer from 1998 to 2012. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 57.e15-57.e22.	0.8	17
198	Variation in Locoregional Prostate Cancer Care and Treatment Trends at Commission on Cancer Designated Facilities: A National Cancer Data Base Analysis 2004 to 2013. Clinical Genitourinary Cancer, 2017, 15, e955-e968.	0.9	17

#	Article	IF	CITATIONS
199	Effect of Nonurothelial Histologic Variants on the Outcomes of Radical Cystectomy for Nonmetastatic Muscle-invasive Urinary Bladder Cancer. Clinical Genitourinary Cancer, 2018, 16, e129-e139.	0.9	17
200	Examining the relationship between complications and perioperative mortality following radical cystectomy: a populationâ€based analysis. BJU International, 2019, 124, 40-46.	1.3	17
201	Risk of dementia following androgen deprivation therapy for treatment of prostate cancer. Prostate Cancer and Prostatic Diseases, 2020, 23, 410-418.	2.0	17
202	Factors predicting prolonged operative time for individual surgical steps of robot-assisted radical prostatectomy (RARP): A single surgeon's experience. Canadian Urological Association Journal, 2015, 9, 417.	0.3	16
203	Effect of Preoperative Angina Pectoris on Cardiac Outcomes in Patients With Previous Myocardial Infarction Undergoing Major Noncardiac Surgery (Data from ACS-NSQIP). American Journal of Cardiology, 2015, 115, 1080-1084.	0.7	16
204	Comparison of 30-day perioperative outcomes in adults undergoing open versus minimally invasive pyeloplasty for ureteropelvic junction obstruction: analysis of 593 patients in a prospective national database. World Journal of Urology, 2015, 33, 2107-2113.	1.2	16
205	Occult High-risk Disease in Clinically Low-risk Prostate Cancer with ≥50% Positive Biopsy Cores: Should National Guidelines Stop Calling Them Low Risk?. Urology, 2016, 87, 125-132.	0.5	16
206	Impact of adequate pelvic lymph node dissection on overall survival after radical cystectomy: A stratified analysis by clinical stage and receipt of neoadjuvant chemotherapy. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 78.e13-78.e19.	0.8	16
207	Cardiovascular toxicities associated with abiraterone compared to enzalutamide–A pharmacovigilance study. EClinicalMedicine, 2021, 36, 100887.	3.2	16
208	Adoption of Technology and Its Impact on Nephrectomy Outcomes, a U.S. Population-Based Analysis (2008–2012). Journal of Endourology, 2017, 31, 91-99.	1.1	15
209	Postoperative sepsis prediction in patients undergoing major cancer surgery. Journal of Surgical Research, 2017, 209, 60-69.	0.8	15
210	Contemporary Management of Prostate Cancer Patients Suitable for Active Surveillance: A North American Population-based Study. European Urology Focus, 2018, 4, 68-74.	1.6	15
211	Cost-effectiveness of Robotic-Assisted Radical Prostatectomy for Localized Prostate Cancer in the UK. JAMA Network Open, 2022, 5, e225740.	2.8	15
212	Open radical prostatectomy in the elderly: a case for concern?. BJU International, 2012, 109, 1335-1340.	1.3	14
213	Association between very small tumour size and increased cancerâ€specific mortality after radical prostatectomy in lymph nodeâ€positive prostate cancer. BJU International, 2016, 118, 279-285.	1.3	14
214	The Effect of Physician Specialty Obtaining Access for Percutaneous Nephrolithotomy on Perioperative Costs and Outcomes. Journal of Endourology, 2017, 31, 1152-1156.	1.1	14
215	Pathologic Outcomes of Gleason 6 Favorable Intermediate-Risk Prostate Cancer Treated With Radical Prostatectomy: Implications for Active Surveillance. Clinical Genitourinary Cancer, 2018, 16, 226-234.	0.9	14
216	Mobile Health App for Prostate Cancer Patients on Androgen Deprivation Therapy: Qualitative Usability Study. JMIR MHealth and UHealth, 2020, 8, e20224.	1.8	14

#	Article	IF	Citations
217	Differential post-prostatectomy cancer-specific survival of occult T3 vs. clinical T3 prostate cancer: Implications for managing patients upstaged on prostate magnetic resonance imaging. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 330.e19-330.e25.	0.8	13
218	Factors associated with the omission of androgen deprivation therapy in radiation-managed high-risk prostate cancer. Brachytherapy, 2016, 15, 695-700.	0.2	13
219	Adverse Event Rates, Timing of Complications, and the Impact of Specialty on Outcomes Following Adrenal Surgery: An Analysis of 30-Day Outcome Data From the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP). Urology, 2016, 90, 62-68.	0.5	13
220	Rho-associated protein kinase 2 (ROCK2): a new target of autoimmunity in paraneoplastic encephalitis. Acta Neuropathologica Communications, 2017, 5, 40.	2.4	13
221	Increased Vulnerability to Poorer Cancer-Specific Outcomes Following Recent Divorce. American Journal of Medicine, 2018, 131, 517-523.	0.6	13
222	Perioperative outcomes after radical cystectomy at NCI-designated centres: Are they any better?. Canadian Urological Association Journal, 2015, 9, 207.	0.3	13
223	Utilization and perioperative outcomes of robotic vaginal vault suspension compared to abdominal or vaginal approaches for pelvic organ prolapse. Canadian Urological Association Journal, 2014, 8, 100.	0.3	12
224	Open Versus Robotic Radical Prostatectomy in Obese Men. Current Urology, 2015, 8, 156-161.	0.4	12
225	Pneumonia after Major Cancer Surgery: Temporal Trends and Patterns of Care. Canadian Respiratory Journal, 2016, 2016, 1-7.	0.8	12
226	Characterizing trends in treatment modalities for localized muscle-invasive bladder cancer in the pre-immunotherapy era. World Journal of Urology, 2018, 36, 1767-1774.	1.2	12
227	United States trends in active surveillance or watchful waiting across patient socioeconomic status from 2010 to 2015. Prostate Cancer and Prostatic Diseases, 2020, 23, 179-183.	2.0	12
228	Differences in survival and impact of adjuvant chemotherapy in patients with variant histology of tumors of the renal pelvis. World Journal of Urology, 2020, 38, 2227-2236.	1.2	12
229	Ambulatory-Based Bladder Outlet Procedures Offer Significant Cost Savings and Comparable 30-Day Outcomes Relative to Inpatient Procedures. Journal of Endourology, 2020, 34, 1248-1254.	1.1	12
230	Racial differences in the treatment and outcomes for prostate cancer in Massachusetts. Cancer, 2021, 127, 2714-2723.	2.0	12
231	Decision regret, adverse outcomes, and treatment choice in men with localized prostate cancer: Results from a multi-site randomized trial. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 493.e9-493.e15.	0.8	12
232	Randomized clinical trial of BCG vaccine in patients with convalescent COVIDâ€19: Clinical evolution, adverse events, and humoral immune response. Journal of Internal Medicine, 2022, 292, 654-666.	2.7	12
233	Re-assessment of 30-, 60- and 90-day mortality rates in non-metastatic prostate cancer patients treated either with radical prostatectomy or radiation therapy. Canadian Urological Association Journal, 2014, 8, 75.	0.3	11
234	Population-based Comparative Effectiveness of Salvage Radical Prostatectomy vs Cryotherapy. Urology, 2014, 83, 653-657.	0.5	11

#	Article	IF	CITATIONS
235	Predicting pathological outcomes in patients undergoing robot-assisted radical prostatectomy for high-risk prostate cancer: a preoperative nomogram. BJU International, 2015, 116, 703-712.	1.3	11
236	Association between Surgeon and Hospital Characteristics and Lymph Node Counts From Radical Prostatectomy and Pelvic Lymph Node Dissection. Urology, 2015, 85, 890-895.	0.5	11
237	Rates of Kidney Transplantation From Living and Deceased Donors for Blacks and Whites in the United States, 1998 to 2011. JAMA Internal Medicine, 2015, 175, 1716.	2.6	11
238	Could lead-time bias explain the apparent benefits of early salvage radiotherapy?. Nature Reviews Urology, 2017, 14, 193-194.	1.9	11
239	Use of Preventive Health Services Among Cancer Survivors in the U.S American Journal of Preventive Medicine, 2018, 55, 830-838.	1.6	11
240	Variation in Positive Surgical Margin Status After Radical Prostatectomy for pT2 Prostate Cancer. Clinical Genitourinary Cancer, 2019, 17, e1060-e1068.	0.9	11
241	Contemporary Survival Rates for Muscle-Invasive Bladder Cancer Treated With Definitive or Non-Definitive Therapy. Clinical Genitourinary Cancer, 2019, 17, e488-e493.	0.9	11
242	Lower odds of cardiac events for gonadotrophinâ€releasing hormone antagonists versus agonists. BJU International, 2020, 126, 9-10.	1.3	11
243	Effect of Medicaid Expansion on Receipt of Definitive Treatment and Time to Treatment Initiation by Racial and Ethnic Minorities and at Minority-Serving Hospitals: A Patient-Level and Facility-Level Analysis of Breast, Colon, Lung, and Prostate Cancer. JCO Oncology Practice, 2021, 17, e654-e665.	1.4	11
244	The Effect of Resident Involvement on Surgical Outcomes for Common Urologic Procedures: A Case Study of Uni- and Bilateral Hydrocele Repair. Urology, 2016, 94, 70-76.	0.5	10
245	Accurately determining patients who underwent robotâ€assisted surgery: limitations of administrative databases. BJU International, 2016, 118, 346-348.	1.3	10
246	Relationship between androgen deprivation therapy and communityâ€acquired respiratory infections in patients with prostate cancer. International Journal of Urology, 2016, 23, 305-311.	0.5	10
247	Variation in National Use of Long-Term ADT by Disease Aggressiveness Among Men With Unfavorable-Risk Prostate Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 421-428.	2.3	10
248	Weighing the evidence from surgical trials. BJU International, 2017, 119, 659-660.	1.3	10
249	The Use of Prostate Specific Antigen Screening in Purchased versus Direct Care Settings: Data from the TRICARE® Military Database. Journal of Urology, 2017, 198, 1295-1300.	0.2	10
250	Understanding the impact and challenges of secondary data analysis. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 163-164.	0.8	10
251	The impact of smoking on radical cystectomy complications increases in elderly patients. Cancer, 2021, 127, 1387-1394.	2.0	10
252	Systematic Review of Time to Definitive Treatment for Intermediate Risk and High Risk Prostate Cancer: Are Delays Associated with Worse Outcomes?. Journal of Urology, 2021, 205, 1263-1274.	0.2	10

#	Article	IF	Citations
253	Accuracy of Transrectal Ultrasonography toÂEvaluate Pathologic Prostate Weight: Correlation With Various Prostate Size Groups. Urology, 2014, 84, 169-174.	0.5	9
254	Contemporary nationwide patterns of self-reported prostate-specific antigen screening in US veterans. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 503.e7-503.e15.	0.8	9
255	National Trends and Predictors of Androgen Deprivation Therapy Use in Low-Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 98, 338-343.	0.4	9
256	Testing the external validity of the EORTC randomized trial 30904 comparing overall survival after radical nephrectomy vs nephronâ€sparing surgery in contemporary North American patients with renal cell cancer. BJU International, 2018, 121, 345-347.	1.3	9
257	Contemporary Treatment Patterns for Non-muscle-invasive Bladder Cancer: Has the Use of Radical Cystectomy Changed in the BCG Shortage Era?. Urology, 2021, 147, 199-204.	0.5	9
258	An evaluation of the $\hat{a} \in \hat{b}$ weekend effect $\hat{a} \in \hat{b}$ in patients admitted with metastatic prostate cancer. BJU International, 2015, 116, 911-919.	1.3	8
259	Patient Characteristics and Perioperative Outcomes of Female Urethral Diverticulectomy: Analysis of a Multi-Institutional Prospective Database. Urology, 2015, 86, 712-715.	0.5	8
260	Fatigue with vascular endothelial growth factor receptor tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors in patients with renal cell carcinoma (RCC) and other malignancies: A meta-analysis of randomized clinical trials. Critical Reviews in Oncology/Hematology, 2015, 95, 251-263.	2.0	8
261	The Contemporary Incidence and Sequelae of Rhabdomyolysis Following Extirpative Renal Surgery: A Population Based Analysis. Journal of Urology, 2016, 195, 399-405.	0.2	8
262	Recommended Cancer Screening in Accountable Care Organizations: Trends in Colonoscopy and Mammography in the Medicare Shared Savings Program. Journal of Oncology Practice, 2019, 15, e547-e559.	2.5	8
263	Prostate cancer in the medicare shared savings program: are Accountable Care Organizations associated with reduced expenditures for men with prostate cancer?. Prostate Cancer and Prostatic Diseases, 2019, 22, 593-599.	2.0	8
264	Implementation of a Perioperative Venous Thromboembolism Prophylaxis Program for Patients Undergoing Radical Cystectomy on an Enhanced Recovery After Surgery Protocol. European Urology Focus, 2020, 6, 74-80.	1.6	8
265	Temporal Trends and Predictors in the Use of Stereotactic Body Radiotherapy for Treatment of Metastatic Renal Cell Carcinoma in the U.S. Oncologist, 2021, 26, e905-e906.	1.9	8
266	Risk of Immune-related Adverse Events in Melanoma Patients With Preexisting Autoimmune Disease Treated With Immune Checkpoint Inhibitors. American Journal of Clinical Oncology: Cancer Clinical Trials, 2021, 44, 413-418.	0.6	8
267	Measuring What Matters: Patient-Reported Outcome and Experience Measures for Men Undergoing Radical Prostatectomy. European Urology Focus, 2021, 7, 913-915.	1.6	8
268	Disproportional signal of sexual dysfunction reports associated with finasteride use in young men with androgenetic alopecia: A pharmacovigilance analysis of VigiBase. Journal of the American Academy of Dermatology, 2023, 88, 179-181.	0.6	8
269	Digital technologies in cancer care: a review from the clinician's perspective. Journal of Comparative Effectiveness Research, 2022, , .	0.6	8
270	Does partial nephrectomy at an academic institution result in better outcomes?. World Journal of Urology, 2012, 30, 505-510.	1.2	7

#	Article	IF	CITATIONS
271	NATIONAL RATES AND RISK FACTORS FOR STENT FAILURE IN PATIENTS WITH OBSTRUCTED, INFECTED UPPER TRACT STONES. Canadian Urological Association Journal, 2015, 9, 164.	0.3	7
272	Treatment patterns, testicular loss and disparities in inpatient surgical management of testicular torsion in boys: a populationâ€based study 1998–2010. BJU International, 2016, 118, 969-979.	1.3	7
273	Complications Following Common Inpatient Urological Procedures: Temporal Trend Analysis from 2000 to 2010. European Urology Focus, 2016, 2, 3-9.	1.6	7
274	Disparities in the Receipt of Local Treatment of Node-positive Prostate Cancer. Clinical Genitourinary Cancer, 2017, 15, 563-569.e3.	0.9	7
275	State-by-state Variation in Prostate-specific Antigen Screening Trends Following the 2011 United States Preventive Services Task Force Panel Update. Urology, 2018, 112, 56-65.	0.5	7
276	Contemporary trends in the utilisation of radical prostatectomy. BJU International, 2018, 122, 726-728.	1.3	7
277	Racial/ethnicity differences in endorsing influential factors for prostate cancer treatment choice: An analysis of data from the personal patient profile-prostate (P3P) I and II trials. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 78.e7-78.e13.	0.8	7
278	Association of Affordable Care Act-related Medicaid expansion with variation in utilization of surgical services. American Journal of Surgery, 2020, 220, 441-447.	0.9	7
279	Quantifying the Overall Survival Benefit With Early Radical Cystectomy for Patients With Histologically Confirmed T1 Non–muscle-invasive Bladder Cancer. Clinical Genitourinary Cancer, 2020, 18, e651-e659.	0.9	7
280	Lessons from Pharmacovigilance: Pulmonary Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy. Lung, 2021, 199, 199-211.	1.4	7
281	Comparison of comorbidity indices for prediction of morbidity and mortality after major surgical procedures. American Journal of Surgery, 2021, 222, 998-1004.	0.9	7
282	Is the current referral trend a threat to the Military Health System? Perioperative outcomes and costs after colorectal surgery in the Military Health System versus civilian facilities. Surgery, 2021, 170, 67-74.	1.0	7
283	Defining Factors Associated with High-quality Surgery Following Radical Cystectomy: Analysis of the British Association of Urological Surgeons Cystectomy Audit. European Urology Open Science, 2021, 33, 1-10.	0.2	7
284	Results of a phase II trial of intense androgen deprivation therapy prior to radical prostatectomy (RP) in men with high-risk localized prostate cancer (PC) Journal of Clinical Oncology, 2020, 38, 5503-5503.	0.8	7
285	Does Veteran Status Mitigate Racial Disparities in Prostate Cancer Screening? Analysis of Prostate Specific Antigen Screening Patterns in the 2018 Behavioral Risk Factor Surveillance System Data. Journal of Urology, 2022, 207, 993-1000.	0.2	7
286	Models of Assessment of Comparative Outcomes of Robot-Assisted Surgery. Urologic Clinics of North America, 2014, 41, 597-606.	0.8	6
287	Association of Androgen Deprivation Therapy With Alzheimer's Disease: Unmeasured Confounders. Journal of Clinical Oncology, 2016, 34, 2801-2803.	0.8	6
288	Risk Assessment in Small Renal Masses. Urologic Clinics of North America, 2017, 44, 189-202.	0.8	6

#	Article	IF	Citations
289	Low rates of androgen deprivation therapy use with salvage radiation therapy in patients with prostate cancer after radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 542.e25-542.e32.	0.8	6
290	Lack of Benefit From the Addition of External Beam Radiation Therapy to Brachytherapy for Intermediate- and High-risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 99, 904-911.	0.4	6
291	Impact of Baseline Characteristics on the Survival Benefit of High-Intensity Local Treatment in Metastatic Urothelial Carcinoma of the Bladder. European Urology Focus, 2018, 4, 568-571.	1.6	6
292	Costs variations for percutaneous nephrolithotomy in the U.S. from 2003–2015: A contemporary analysis of an all-payer discharge database. Canadian Urological Association Journal, 2018, 12, .	0.3	6
293	Testosterone replacement therapy is associated with an increased risk of urolithiasis. World Journal of Urology, 2019, 37, 2737-2746.	1.2	6
294	Multilevel Analysis of Readmissions After Radical Cystectomy for Bladder Cancer in the USA: Does the Hospital Make a Difference?. European Urology Oncology, 2019, 2, 349-354.	2.6	6
295	Comparison of testis cancerâ€specific survival: an analysis of national cancer registry data from the USA, UK and Germany. BJU International, 2019, 123, 385-387.	1.3	6
296	Minimally invasive cancer surgery is associated with a lower risk of venous thromboembolic events. Journal of Surgical Oncology, 2020, 121, 578-583.	0.8	6
297	Delayed nephrectomy has comparable long-term overall survival to immediate nephrectomy for cT1a renal cell carcinoma: A population-based analysis. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 74.e13-74.e20.	0.8	6
298	Impact of hospital and surgeon volumes on short-term and long-term outcomes of radical cystectomy. Current Opinion in Urology, 2020, Publish Ahead of Print, 701-710.	0.9	6
299	Inequity in selective referral to high-volume hospitals for genitourinary malignancies. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 582-589.	0.8	6
300	The Relationship Between Health Literacy and Nonrecommended Cancer Screening. American Journal of Preventive Medicine, 2021, 60, e69-e72.	1.6	6
301	Impact of preoperative plasma levels of interleukin 6 and interleukin 6 soluble receptor on disease outcomes after radical cystectomy for bladder cancer. Cancer Immunology, Immunotherapy, 2022, 71, 85-95.	2.0	6
302	Adjuvant versus neoadjuvant chemotherapy for muscle-invasive bladder cancer (MIBC): Analysis of the National Cancer Database (NCDB) Journal of Clinical Oncology, 2016, 34, 4524-4524.	0.8	6
303	Geographic Variability, Time Trends and Association of Preoperative Magnetic Resonance Imaging with Surgical Outcomes for Elderly United States Men with Prostate Cancer: A Surveillance, Epidemiology, and End Results-Medicare Analysis. Journal of Urology, 2022, 208, 609-617.	0.2	6
304	Robot-assisted urological surgery: Current status and future perspectives. Arab Journal of Urology Arab Association of Urology, 2012, 10, 17-22.	0.7	5
305	Re: Pazopanib Versus Sunitinib in Metastatic Renal-cell Carcinoma. European Urology, 2014, 65, 1014-1015.	0.9	5
306	Prevalence of Nonrecommended Screening for Prostate Cancer and Breast Cancer in the United States. JAMA Oncology, 2016, 2, 543.	3.4	5

#	Article	IF	Citations
307	Do micropapillary patients benefit from chemotherapy?. BJU International, 2017, 119, 656-658.	1.3	5
308	Assessing robot-assisted laparoscopic prostatectomy. Lancet, The, 2017, 389, 799.	6.3	5
309	The current landscape of low-value care in men diagnosed with prostate cancer: what is the role of individual hospitals?. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 575.e9-575.e18.	0.8	5
310	Trends in Adherence to Thromboprophylaxis Guideline in Patients Undergoing Radical Cystectomy. Urology, 2020, 135, 44-49.	0.5	5
311	Temporal Trends in the Incidence of Testicular Cancer in the United States over the Past Four Decades. European Urology Oncology, 2021, 4, 834-836.	2.6	5
312	Early continence after ileal neobladder: objective data from inpatient rehabilitation. World Journal of Urology, 2021, 39, 2531-2536.	1.2	5
313	Accounting for Readiness—Integrating Time-Driven Activity-Based Costing (TDABC) into the Military Health System. Military Medicine, 2020, 185, e930-e933.	0.4	5
314	Prostate cancer and kidney transplantation – exclusion or coâ€existence?. BJU International, 2020, 125, 628-629.	1.3	5
315	Comparison of prostate cancer detection rates in patients undergoing MRI/TRUS fusion prostate biopsy with two different softwareâ€based systems. Prostate, 2021, , .	1.2	5
316	Comparison between complication rates of laser prostatectomy electrocautery transurethral resection of the prostate: A population-based study. Canadian Urological Association Journal, 2014, 8, 419.	0.3	4
317	Data on Medicare eligibility and cancer screening utilization. Data in Brief, 2016, 7, 679-681.	0.5	4
318	Risk of Small Bowel Obstruction After Robot-Assisted <i>vs</i> Open Radical Prostatectomy. Journal of Endourology, 2016, 30, 1291-1295.	1.1	4
319	Trends in Prostate-Specific Antigen Screening Since the Implementation of the 2012 US Preventive Services Task Force Recommendations. European Urology Focus, 2018, 4, 1002-1004.	1.6	4
320	Impact of Index Surgical Care Setting on Perioperative Outcomes and Cost Following Penile Prosthesis Surgery. Journal of Sexual Medicine, 2019, 16, 1451-1458.	0.3	4
321	Re: Ronald D. Ennis, Liangyuan Hu, Shannon N. Ryemon, Joyce Lin, Madhu Mazumdar. Brachytherapy-based Radiotherapy and Radical Prostatectomy Are Associated with Similar Survival in High-risk Localized Prostate Cancer. J Clin Oncol 2018;36:1192–8. European Urology Oncology, 2019, 2, 227-223.	2.6	4
322	Health care spending in prostate cancer: An assessment of characteristics and health care utilization of high resource-patients. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 130.e17-130.e24.	0.8	4
323	Is Medicaid expansion associated with increases in palliative treatments for metastatic cancer?. Journal of Comparative Effectiveness Research, 2021, 10, 733-741.	0.6	4
324	Impact of high-intensity local treatment on overall survival in stage IV upper tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 436.e1-436.e10.	0.8	4

#	Article	IF	CITATIONS
325	Recovery from minimally invasive vs. open surgery in kidney cancer patients: Opioid use and workplace absenteeism. Investigative and Clinical Urology, 2021, 62, 56.	1.0	4
326	Facility Level Variation in Rates of Definitive Therapy for Low Risk Prostate Cancer in Men with Limited Life Expectancy: An Opportunity for Value Based Care Redesign. Journal of Urology, 2019, 201, 728-734.	0.2	4
327	Combination of Tadalafil and Finasteride for the Treatment of Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia: Commercialization of the Prescribing Cascade. European Urology, 2022, 81, 323-324.	0.9	4
328	Neurocognitive impairment associated with traditional and novel androgen receptor signaling inhibitors ± androgen deprivation therapy: a pharmacovigilance study. Prostate Cancer and Prostatic Diseases, 2022, , .	2.0	4
329	A critical appraisal of systemic treatment options for metastatic non-clear cell renal cell carcinoma. Critical Reviews in Oncology/Hematology, 2014, 90, 49-57.	2.0	3
330	Perceptions of Radiation Oncologists and Urologists onÂSources and Type of Evidence to Inform Prostate Cancer Treatment Decisions. International Journal of Radiation Oncology Biology Physics, 2014, 89, 277-283.	0.4	3
331	The Controversy That Will Not Go Away. European Urology, 2015, 67, 439-440.	0.9	3
332	Facility-Level Variation in Pelvic Lymphadenectomy During Radical Prostatectomy and Effect on Overall Survival in Men with High-Risk Prostate Cancer. Annals of Surgical Oncology, 2020, 27, 1929-1936.	0.7	3
333	Care Setting as a Modifiable Predictor of Perioperative Cost and Outcomes following Elective Urinary Stone Surgery. Urology Practice, 2020, 7, 259-265.	0.2	3
334	Changing the Prostate Cancer Detection Paradigm: Clinical Application of European Association of Urology Guideline–recommended Magnetic Resonance Imaging–based Risk Stratification in Men with Suspected Prostate Cancer. European Urology Focus, 2020, 7, 1011-1018.	1.6	3
335	Institutional Adoption and Apprenticeship of Fusion Targeted Prostate Biopsy: Does Experience Affect the Cancer Detection Rate?. Urologia Internationalis, 2020, 104, 476-482.	0.6	3
336	Trends in mortality among Black and White men with prostate cancer in Massachusetts and Pennsylvania: Race and neighborhood socioeconomic position. Cancer, 2021, 127, 2525-2534.	2.0	3
337	Prognostic value of the pre-operative serum albumin to globulin ratio in patients with non-metastatic prostate cancer undergoing radical prostatectomy. International Journal of Clinical Oncology, 2021, 26, 1729-1735.	1.0	3
338	Delay in surgery for cT1b-2 kidney cancer beyond 90 days is associated with poorer survival: implications for prioritization during the COVID-19 pandemic. Minerva Urology and Nephrology, 2021, 73, 404-406.	1.3	3
339	Neurotoxicities of novel non-steroidal anti-androgens for prostate cancer: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2021, 166, 103463.	2.0	3
340	Receipt of Survivorship Care Plans and Self-Reported Health Status among Patients with Genitourinary Malignancy. Journal of Urology, 2020, 204, 564-569.	0.2	3
341	Comparison of the treatment of men with prostate cancer between the US and England: an international population-based study. Prostate Cancer and Prostatic Diseases, 2023, 26, 287-292.	2.0	3
342	Anti-Androgen Therapy Overcomes the Time Delay in Initiation of Salvage Radiation Therapy and Rescues the Oncological Outcomes in Men with Recurrent Prostate Cancer After Radical Prostatectomy: A Post Hoc Analysis of the RTOG-9601 Trial Data. Annals of Surgical Oncology, 2022, 29, 7206-7215.	0.7	3

#	Article	IF	CITATIONS
343	Inpatients hypospadias care: Trends and outcomes from the American nationwide inpatient sample. Korean Journal of Urology, 2015, 56, 594.	1.2	2
344	Complications After Surgery for Stress Urinary Incontinence. JAMA Surgery, 2015, 150, 1175.	2.2	2
345	Observational Studies to Contextualize Surgical Trials. European Urology, 2016, 70, 231-232.	0.9	2
346	Re: Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: A Randomized Clinical Trial. European Urology, 2016, 69, 963-964.	0.9	2
347	New evidence from the Prostate Cancer Prevention Trial may exculpate cyclooxygenase (<scp>COX</scp>) blockers in erectile dysfunction. BJU International, 2016, 117, 385-386.	1.3	2
348	Targeted Cancer Screening After Solid-Organ Transplantation. JAMA Oncology, 2016, 2, 470.	3.4	2
349	Challenging Residual Contamination of Instruments for Robotic Surgery in Japan. Infection Control and Hospital Epidemiology, 2017, 38, 501-502.	1.0	2
350	Does Low-value Care Affect Urologists?. European Urology, 2017, 71, 304-305.	0.9	2
351	Adoption of robotic surgery: driven by market competition or a desire to improve patient care?. Lancet Oncology, The, 2018, 19, e66.	5.1	2
352	Contemporary perceptions of human papillomavirus and penile cancer: Perspectives from a national survey. Canadian Urological Association Journal, 2018, 13, 32-37.	0.3	2
353	Multiparametric magnetic resonance imaging for prostate cancer detection: do clinical trial findings reflect realâ€world practice?. BJU International, 2019, 123, 197-198.	1.3	2
354	Suicide Risk Among Patients with Genitourinary Malignancies: Where Do We Stand?. European Urology Focus, 2020, 6, 1145-1146.	1.6	2
355	Association of surgical approach and prolonged opioid prescriptions in patients undergoing major pelvic cancer procedures. BMC Surgery, 2020, 20, 235.	0.6	2
356	Impact of percent positive biopsy cores on cancer-specific mortality for patients with high-risk prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 735.e9-735.e15.	0.8	2
357	Prostate cancer management costs vary by disease stage at presentation. Prostate Cancer and Prostatic Diseases, 2020, 23, 564-566.	2.0	2
358	All for one, one for all: is centralisation the way to go?. BJU International, 2020, 125, 191-192.	1.3	2
359	Workplace absenteeism amongst patients undergoing open vs. robotic radical prostatectomy, hysterectomy, and partial colectomy. Surgical Endoscopy and Other Interventional Techniques, 2021, 35, 1644-1650.	1.3	2
360	Temporal trends in the incidence of distantâ€stage bladder cancer among young individuals. International Journal of Urology, 2021, 28, 704-705.	0.5	2

#	Article	IF	CITATIONS
361	Association of Hair Loss With Suicidality and Psychological Adverse Events vs Finasteride Use—Reply. JAMA Dermatology, 2021, 157, 738.	2.0	2
362	Predicting survival after radical prostatectomy: Variation of machine learning performance by race. Prostate, 2021, 81, 1355-1364.	1.2	2
363	Limitations of using the National Cancer Database to examine the effect of policy change on stage at presentation at the population level. Journal of the American Academy of Dermatology, 2021, 85, e195-e196.	0.6	2
364	Health literacy is a barrier to shared decision making in early prostate cancer (PCA) among African American (AA) men Journal of Clinical Oncology, 2019, 37, 84-84.	0.8	2
365	Psychosocial Distress in the Early Recovery Period after Radical Prostatectomy. Urologia Internationalis, 2022, 106, 891-896.	0.6	2
366	Prognostic value of hepatocyte growth factor for muscle-invasive bladder cancer. Journal of Cancer Research and Clinical Oncology, 2022, 148, 3091-3102.	1.2	2
367	Association between Operative Time and Short-Term Radical Cystectomy Complications. Urologia Internationalis, 2023, 107, 273-279.	0.6	2
368	The cost impact of disease progression to metastatic castration-sensitive prostate cancer. Journal of Managed Care & Decialty Pharmacy, 2022, 28, 544-554.	0.5	2
369	Measuring the Effectiveness of Androgen-Deprivation Therapy for Prostate Cancer in the Medicare Population. JAMA Internal Medicine, 2014, 174, 1468.	2.6	1
370	Prevalence and risk factors of contralateral extraprostatic extension in men undergoing radical prostatectomy for unilateral disease at biopsy: A global multi-institutional experience. Canadian Urological Association Journal, 2015, 9, 434.	0.3	1
371	Immortalâ€time bias: a crucial yet overlooked confounder in urological research. BJU International, 2017, 120, 455-455.	1.3	1
372	Reply from Authors re: Girish S. Kulkarni, Zachary Klaassen. Trimodal Therapy is Inferior to Radical Cystectomy for Muscle-invasive Bladder Cancer using Population-level Data: Is There Evidence in the (Lack of) Details? Eur Urol 2017;72:488–9. European Urology, 2017, 72, 489-491.	0.9	1
373	Comparative Effectiveness of Transurethral Resection Techniques in the Inpatient Setting for Benign Prostatic Hyperplasia. Urology Practice, 2018, 5, 377-382.	0.2	1
374	Reply to Aditya Bagrodia, Solomon Woldu, David F. Penson, Alexander Kutikov, and Samuel D. Kaffenberger's Letter to the Editor re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. Eur Urol 2018;73:262–70. European Urology, 2018, 73, e100-e101.	0.9	1
375	Investigating the effect of treatment at high-volume hospitals on overall survival following cytoreductive nephrectomy. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 400.e15-400.e22.	0.8	1
376	Machines in urology: a brief odyssey of the future. BJU International, 2019, 124, 545-546.	1.3	1
377	Three-tiered Subclassification System of High-risk Prostate Cancer in Men Managed With Radical Prostatectomy: Implications for Treatment Decision-making. Urology, 2020, 145, 197-203.	0.5	1
378	Real-world comparative effectiveness of shockwave lithotripsy versus ureterorenoscopy for the treatment of urinary stones. World Journal of Urology, 2021, 39, 2177-2182.	1.2	1

#	Article	IF	Citations
379	Delayed blood transfusion is associated with mortality following radical cystectomy. Scandinavian Journal of Urology, 2020, 54, 290-296.	0.6	1
380	Meditative and mind-body practice among patients with genitourinary malignancy. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 192.e15-192.e20.	0.8	1
381	Nephrotoxicity of immune checkpoint inhibitor therapy: a pharmacovigilance study. Nephrology Dialysis Transplantation, 2021, , .	0.4	1
382	Association of the hospital readmission reduction program with readmission and mortality outcomes after coronary artery bypass graft surgery. Journal of Cardiac Surgery, 2021, 36, 3251-3258.	0.3	1
383	ASO Visual Abstract: Cancer in the Shadow of COVID: Early-Stage Breast and Prostate Cancer Patient Perspectives on Surgical Delays Due to COVID-19. Annals of Surgical Oncology, 2021, 28, 545.	0.7	1
384	High-intensity local treatment of clinical node-positive urothelial carcinoma of the bladder alongside systemic chemotherapy improves overall survival. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 62.e1-62.e11.	0.8	1
385	Robot-Assisted Partial Nephrectomy Using Robotically Applied Bulldog Clamps for Hilar Clamping: Initial Series, Technique, and Outcomes. Videourology (New Rochelle, N Y), 2011, 25, .	0.1	1
386	Urethrovesical Anastomosis Using Barbed Suture During Robot-Assisted Radical Prostatectomy. Videourology (New Rochelle, N Y), 2011, 25, .	0.1	1
387	Comparative effectiveness of radical cystectomy versus bladder-sparing treatment for muscle-invasive urothelial carcinoma: A population-based report Journal of Clinical Oncology, 2014, 32, 334-334.	0.8	1
388	The impact of histological variants on bladder cancer survival: A population-based analysis Journal of Clinical Oncology, 2016, 34, 458-458.	0.8	1
389	Impact of variant histology on disease-specific mortality and survival in patients with non-muscle invasive bladder cancer (NMIBC): A population-based analysis Journal of Clinical Oncology, 2017, 35, 332-332.	0.8	1
390	Providers' inability to estimate health literacy among African American (AA) patients (pts) with early prostate cancer (PCa) Journal of Clinical Oncology, 2019, 37, 77-77.	0.8	1
391	Understanding the roles of randomized trials for robotic prostatectomy. Annals of Translational Medicine, 2016, 4, 467-467.	0.7	1
392	The association of androgen deprivation therapy and anxiety among 78,000 patients with localized prostate cancer patients Journal of Clinical Oncology, 2017, 35, 19-19.	0.8	1
393	Efficacy of local treatment in patients with prostate cancer with clinically pelvic lymph node-positive disease at initial diagnosis Journal of Clinical Oncology, 2017, 35, 164-164.	0.8	1
394	Adverse effects of ADT on cognitive function and dementia for men with prostate cancer: A meta-analysis and systematic review Journal of Clinical Oncology, 2017, 35, 150-150.	0.8	1
395	Contemporary incidence and epidemiologic trends of brain metastases at renal cell carcinoma diagnosis Journal of Clinical Oncology, 2017, 35, 529-529.	0.8	1
396	Identification of low prostate-specific antigen, high Gleason prostate cancer as a unique hormone-resistant entity with poor survival: A contemporary analysis of 640,000 patients Journal of Clinical Oncology, 2017, 35, 5080-5080.	0.8	1

#	Article	IF	CITATIONS
397	Radical prostatectomy for high-risk prostate cancer Opinion: YES. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2019, 45, 424-427.	0.7	1
398	Temporal changes in the screening, diagnosis and surgical treatment of genitourinary (GU) malignancies during the COVID-19 pandemic Journal of Clinical Oncology, 2022, 40, 281-281.	0.8	1
399	Are work relative value units correlated with operative duration of common surgical procedures?. American Journal of Managed Care, 2022, 28, 148-151.	0.8	1
400	Hormone Treatment of Prostate Cancer:. Urologic Clinics of North America, 2022, 49, 309-321.	0.8	1
401	Access to definitive treatment and survival for intermediate-risk and high-risk prostate cancer at hospital systems serving health disparity populations Journal of Clinical Oncology, 2022, 40, 6555-6555.	0.8	1
402	Predicting Other-cause Mortality: The Minimalistic Approach. European Urology, 2014, 66, 1010-1011.	0.9	0
403	Editorial Comment. Urology, 2014, 83, 630-631.	0.5	0
404	How can we improve surgical outcomes?. BJU International, 2015, 116, 835-836.	1.3	0
405	Reply. Urology, 2015, 85, 349-350.	0.5	0
406	Reply to Michael Froehner, Rainer Koch, Manfred P. Wirth's Letter to the Editor re: Jesse D. Sammon, Firas Abdollah, Anthony D'Amico, et al. Predicting Life Expectancy in Men Diagnosed with Prostate Cancer. Eur Urol 2015;68:756–65. European Urology, 2016, 69, e129.	0.9	0
407	S&T-46 COMPARISON OF GLEASON SCORE MISCLASSIFICATION BETWEEN TRANSRECTAL ULTRASOUND â€" MAGNETIC RESONANCE IMAGING FUSION GUIDED PROSTATE BIOPSIES AND SYSTEMATIC BIOPSIES. A PROSPECTIVE ANALYSIS ACCORDING TO FINAL HISTOPATHOLOGY AFTER PROSTATECTOMY Journal of Urology, 2016, 195, .	0.2	0
408	Editorial Comment. Urology, 2016, 87, 86-87.	0.5	0
409	Assessing the Contemporary Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: Another Step in the Right Direction. European Urology, 2016, 69, 92-93.	0.9	0
410	Editorial Comment. Journal of Urology, 2017, 197, 1206-1207.	0.2	0
411	Emergency Department Utilization in Patients With Neurogenic Bladder: Contemporary Burden and National Trends in Prevalence, Inpatient Admission, and Associated Charges, 2006-2011. Urology, 2017, 109, 74-81.	0.5	0
412	Efficient Computation of Reduced Regression Models. American Statistician, 2017, 71, 171-176.	0.9	0
413	Reply to C. Buttigliero et al and B. Biswas et al. Journal of Clinical Oncology, 2017, 35, 1266-1267.	0.8	0
414	Reply to Christian D. Fankhauser, Nico C. Grossmann, Joerg Beyer, and Thomas Hermanns' Letter to the Editor re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. Eur Urol 2018;73:262–70 European Urology, 2018, 73, e96-e97.	0.9	0

#	Article	IF	CITATIONS
415	The new frontier of prostate biopsy: determining the role of imageâ€guidance in moving the needle. BJU International, 2018, 121, 4-5.	1.3	O
416	Evaluation of magnetic resonance imaging and targeted biopsy: The difficulty of finding the right reference standard. Cancer, 2018, 124, 1299-1300.	2.0	0
417	Comparing Adjuvant vs Early-Salvage Radiotherapy After Radical Prostatectomy. JAMA Oncology, 2018, 4, 1619.	3.4	0
418	EDITORIAL COMMENT. Urology, 2019, 130, 84-85.	0.5	0
419	Reply to Amar U. Kishan, William Hall, and Daniel Spratt's Letter to the Editor re: Sebastian Berg, Alexander P. Cole, Marieke J. Krimphove, et al. Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in Patients with High-risk Localized Prostate Cancer. Eur Urol 2019;75:552–5 Comparing Apples to Oranges: A Self-fulfilling Prophecy?.	0.9	0
420	European Urology, 2019, 75, e135-e136. Trimodal Therapy for Bladder Cancer. JAMA Surgery, 2019, 154, e191637.	2.2	0
421	Reply to Michael Froehner and Christian Thomas's Letter to the Editor re: Sebastian Berg, Alexander P. Cole, Marieke J. Krimphove, et al. Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in Patients with High-risk Localized Prostate Cancer. Eur Urol 2019:75:552–5. European Urology. 2019. 76. e76-e77.	0.9	0
422	Leveraging the Full Potential of Clinical Registries. European Urology Focus, 2019, 5, 109-110.	1.6	0
423	Using Cox Regression to Develop Linear Rank Tests with Zero-Inflated Clustered Data. Journal of the Royal Statistical Society Series C: Applied Statistics, 2020, 69, 393-411.	0.5	0
424	Probability of Prostate Cancer Diagnosis following Negative Systematic and Targeted MRI: Transrectal Ultrasound Fusion Biopsy: A Real-Life Observational Study. Urologia Internationalis, 2021, 105, 446-452.	0.6	0
425	A New Era in Surgical Evaluation—What Is at Stake?. JAMA Surgery, 2021, 156, e206360.	2.2	0
426	Reply by Authors. Journal of Urology, 2021, 205, 1274-1274.	0.2	0
427	Reply to: Axel Heidenreich. Still Unanswered: The Role of Extended Pelvic Lymphadenectomy in Improving Oncological Outcomes in Prostate Cancer. Eur Urol 2021;79:605–6. European Urology, 2021, 79,607-608. Reply to Alberto Briganti, Giorgio Gandaglia, Markus Graefen, Steven Joniau, R. Jeffrey Karnes, and Francesco Montergia F. Montergia Gibbot State of the Editor revision F. D. Lectingia Gibbota B. Cuglishmetti, Oues Dien	0.9	O
428	Trinh, et al. Extended Versus Limited Pelvic Lymph Node Dissection During Radical Prostatectomy for Intermediate- and High-risk Prostate Cancer: Early Oncological Outcomes from a Randomized Phase 3 Trial. Eur Urol 2021;79:595–604. Time for a Change? Clinically Meaningful Reasons Why We Will	0.9	0
429	Continue Performin. European Urology, 2021, 79, e184-e185. Robot-Assisted Partial Nephrectomy. Videourology (New Rochelle, N Y), 2011, 25, .	0.1	0
430	Association of partial nephrectomy and presence of robotic surgery for kidney cancer in the United States Journal of Clinical Oncology, 2014, 32, 484-484.	0.8	O
431	Association between provider-level factors and lymph node dissection outcomes during radical prostatectomy: A national cancer database analysis Journal of Clinical Oncology, 2015, 33, 89-89.	0.8	0
432	Fatigue with vascular endothelial growth factor receptor tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors in patients with malignancies: A meta-analysis of randomized clinical trials Journal of Clinical Oncology, 2015, 33, e15583-e15583.	0.8	0

#	Article	IF	CITATIONS
433	Prevalence of non-recommended screening for prostate cancer and breast cancer in the United States Journal of Clinical Oncology, 2015, 33, e17528-e17528.	0.8	O
434	Variation in national use of long-term ADT by disease aggressiveness among men with unfavorable-risk prostate cancer Journal of Clinical Oncology, 2016, 34, 54-54.	0.8	0
435	National predictors and trends for androgen deprivation therapy use in low-risk prostate cancer Journal of Clinical Oncology, 2017, 35, 50-50.	0.8	O
436	Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States Journal of Clinical Oncology, 2017, 35, 18-18.	0.8	0
437	Is neoadjuvant chemotherapy beneficial before radical cystectomy? Examining the external validity of the SWOG-8710 trial Journal of Clinical Oncology, 2017, 35, 331-331.	0.8	0
438	Adverse effects of androgen deprivation therapy on cognitive impairment for men with prostate cancer: A meta-analysis Journal of Clinical Oncology, 2017, 35, e16506-e16506.	0.8	0
439	Outcomes of elderly patients with muscle invasive bladder cancer (MIBC) treated with cystectomy or radiation therapy (RT): A surveillance epidemiology and end results (SEER) database analysis Journal of Clinical Oncology, 2017, 35, e16001-e16001.	0.8	0
440	Impact of sexual orientation on contemporary rates of prostate cancer screening Journal of Clinical Oncology, 2018, 36, 122-122.	0.8	0
441	"Management Migration―in United States patients diagnosed with localized prostate cancer from 2010-2015 Journal of Clinical Oncology, 2019, 37, 11-11.	0.8	0
442	Response to Loughlin re: "Ambulatory-Based Bladder Outlet Procedures Offer Significant Cost Savings and Comparable 30-Day Outcomes Relative to Inpatient Surgery―by Nguyen et al Journal of Endourology, 2020, 34, 1256-1257.	1.1	0
443	Impact of MRI on outcomes in active surveillance (AS) for localized prostate cancer in a hospital registry Journal of Clinical Oncology, 2020, 38, 280-280.	0.8	0
444	Racial/ethnicity differences when endorsing influential factors for prostate cancer treatment choice: An analysis of data from the personal patient profile-prostate (P3P) I and II trials Journal of Clinical Oncology, 2020, 38, 351-351.	0.8	0
445	Reply by Authors. Journal of Urology, 2020, 204, 569-569.	0.2	0
446	How Many Cores Should Be Sampled during Systematic Prostate Biopsy in Case of Negative Multiparametric Magnetic Resonance Imaging? Analysis of 274 Men with Clinical Suspicion of Prostate Cancer. Urologia Internationalis, 2021, , 1-6.	0.6	0
447	Risk and predictors of ipilimumab-associated cardiac adverse events among patients treated for melanoma: A national cohort analysis Journal of Clinical Oncology, 2022, 40, e14592-e14592.	0.8	0
448	Trends in Launch Prices and Price Increases for New Medicines for Urological Cancers. Journal of Urology, 0, , .	0.2	0